The DOI matches its Crossref record.
Epratuzumab, a Humanized Anti-CD22 Antibody, in Aggressive Non-Hodgkin’s Lymphoma
Abstract
Purpose: We conducted a single-center, dose-escalation study evaluating the safety, pharmacokinetics, and efficacy of epratuzumab, an anti-CD22 humanized monoclonal antibody, in patients with aggressive non-Hodgkin’s lymphoma. Experimental Design: Epratuzumab was administered once weekly for 4 weeks at 120-1000-mg/m2 doses to 56 patients [most (n = 35) with diffuse large B-cell lymphoma]. Results: Patients were heavily pretreated (median, 4 prior therapies), 25% received prior high-dose chemotherapy with stem cell transplant, and 84% had bulky disease (≥5 cm). Epratuzumab was well tolerated, with no dose-limiting toxicity. Most (95%) infusions were completed within 1 h. The mean serum half-life was 23.9 days. Across all dose levels and histologies, objective responses (ORs) were observed in five patients (10%; 95% confidence interval, 3–21%), including three complete responses. In patients with diffuse large B-cell lymphoma, 15% had ORs. Overall, 11 (20%) patients experienced some tumor mass reduction. Median duration of OR was 26.3 weeks, and median time to progression for responders was 35 weeks. Two responses are ongoing at ≥34 months, including one rituximab-refractory patient. Conclusions: These data demonstrate that epratuzumab has a good safety profile and exerts antitumor activity in aggressive non-Hodgkin’s lymphoma at doses of ≥240 mg/m2, thus warranting further evaluation in this clinical setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Monoclonal antibody therapy of cancer
Adams, G. P., & Weiner, L. M. (2005) · Nature Biotechnology · doi:10.1038/nbt1137 · Cited by 1,246
Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion
Hudak, J. E., Canham, S. M., & Bertozzi, C. R. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1388 · Cited by 485
Targeted Radionuclide Therapy of Human Tumors
Gudkov, S., Shilyagina, N., Vodeneev, V., & Zvyagin, A. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms17010033 · Cited by 456
Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma
Cheson, B. D., & Leonard, J. P. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708875 · Cited by 438
Self-citationDörner, T., Kaufmann, J., Wegener, W. A., Teoh, N., Goldenberg, D. M., & Burmester, G. R. (2006) · Arthritis Research & Therapy · doi:10.1186/ar1942 · Cited by 306
Self-citation
Metadata
- Authors
- Leonard, J. P., Coleman, M., Ketas, J. C., Chadburn, A., Furman, R., Schuster, M. W., Feldman, E. J., Ashe, M., Schuster, S. J., Wegener, W. A., Hansen, H. J., Ziccardi, H., Eschenberg, M., Gayko, U., Fields, S. Z., Cesano, A., & Goldenberg, D. M.
- Venue
- Clinical Cancer Research
- Published
- 2004-08-15
- Volume
- 10
- Issue
- 16
- Pages
- 5327-5334
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2126422041
- Cited by
- 226
- References
- 0
- FWCI
- 12.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Epratuzumab, a Humanized Anti-CD22 Antibody, in Aggressive Non-Hodgkin’s Lymphoma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-04-0294
- The paper
- Leonard, J. P., Coleman, M., Ketas, J. C., Chadburn, A., Furman, R., Schuster, M. W., Feldman, E. J., Ashe, M., Schuster, S. J., Wegener, W. A., Hansen, H. J., Ziccardi, H., Eschenberg, M., Gayko, U., Fields, S. Z., Cesano, A., & Goldenberg, D. M. (2004). Epratuzumab, a Humanized Anti-CD22 Antibody, in Aggressive Non-Hodgkin’s Lymphoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-04-0294
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.